| Cat.No. | Name | Information |
|---|---|---|
| M2030 | Apremilast | Apremilast is a novel, orally available small molecule inhibitor of PDE4 with IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM. |
| M6804 | IBMX | IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. |
| M14503 | GSK256066 Trifluoroacetate | GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease. |
| M14502 | Deltasonamide 2 (TFA) | Deltasonamide 2 TFA is competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM. |
| M14501 | Deltasonamide 2 hydrochloride | Deltasonamide 2 hydrochloride is a competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM. |
| M14500 | Osoresnontrine | Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC50, 1.4 µM), PDE1C (IC50, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC50 all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders. |
| M11452 | PAT-505 | PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma, respectively. |
| M10870 | Orismilast | Orismilast (LEO-32731) is an orally active phosphodiesterase 4 (PDE4) inhibitor for use in inflammatory diseases and studies related to plaque psoriasis. |
| M10809 | CRT0273750 | CRT0273750 is a lead compound of autotaxin (ATX) inhibitors and regulates plasma LPA levels. CRT0273750 can be used in ATX/LPA dependent cancer models. |
| M8742 | Drotaverine hydrochloride | Drotaverine (Drotaverin) is an isoquinoline-based PDE4-selective phosphodiesterase (PDE) inhibitor and an L-type voltage-dependent (voltage-operated) calcium channel (L-VDCC or L-VOCC) blocker that exhibits in vivo antispasmodic efficacy without anticholinergic effects. |
| M7635 | BAY 73-6691 | BAY 73-6691 was characterized in vitro as the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment of Alzheimer′s disease. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
